|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Par Pharmaceutical, Inc. |
|---|---|
| Collaborator: |
Quintiles |
| Information provided by: | Par Pharmaceutical, Inc. |
| ClinicalTrials.gov Identifier: | NCT00637572 |
Purpose
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections Unintended Weight Loss Cachexia Anorexia AIDS Wasting Syndrome HIV Wasting Syndrome |
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL Drug: Megestrol acetate oral suspension 40 mg/mL |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized, Open-Labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-Related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace) |
| Enrollment: | 63 |
| Study Start Date: | December 2004 |
| Study Completion Date: | June 2005 |
| Primary Completion Date: | June 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Megestrol acetate oral suspension nanocrystal dispersion formulation
|
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
Other Name: Megace ES
|
|
Active Comparator: 2
Megestrol acetate oral suspension micronized formulation
|
Drug: Megestrol acetate oral suspension 40 mg/mL
Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
Other Name: Megace
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Pennsylvania | |
| Drexel University College of Medicine | |
| Philadelphia, Pennsylvania, United States, 19102 | |
| India | |
| M.S. Ramaiah Medical College and Hospital | |
| Bangalore, Karnataka, India, 560054 | |
| Victoria Hospital | |
| Bangalore, Karnataka, India, 560002 | |
| Kasturba Medical College | |
| Mangalore, Karnataka, India, 575003 | |
| Ruby Hall Clinic and Grant Medical Foundation | |
| Pune, Maharashtra, India, 411001 | |
| South Africa | |
| St Mary's Hospital | |
| Private Bag, Ashwood, South Africa, 3605 | |
| Quinta-research | |
| Pellissier, Bloemfontein, South Africa, 9317 | |
| Genclin Corporation, Clinical Trial Centre | |
| Westdene, Bloemfontein, South Africa, 9301 | |
| 40 Arthur Hobbs Street | |
| Boksburg, Johannesburg, South Africa, 1466 | |
| 6 Calypso Centre | |
| Richards Bay, Kwazulu Natal, South Africa, 3900 | |
| Eastmed Hospital | |
| Eastlynn, Pretoria, South Africa, 0186 | |
| TrialTech Clinical Research | |
| Hatfield, Pretoria, South Africa, 0001 | |
| Principal Investigator: | Jan Fourie, MD | 58 Ann Street, Dundee, KZ-Natal 3000, S. Africa |
More Information
| Responsible Party: | VP Clinical and Medical Affairs, Par Pharmaceutical, Inc |
| ClinicalTrials.gov Identifier: | NCT00637572 History of Changes |
| Other Study ID Numbers: | PAR-002 |
| Study First Received: | March 11, 2008 |
| Last Updated: | April 1, 2008 |
| Health Authority: | United States: Food and Drug Administration |
|
Weight loss Cachexia Anorexia Megestrol acetate oral suspension Nanocrystal dispersion Nanocrystal technology Body weight changes |
AIDS wasting HIV wasting Emaciation Megace ES Megace Treatment Experienced |
|
HIV Infections Acquired Immunodeficiency Syndrome Anorexia Body Weight Cachexia Wasting Syndrome Weight Gain Weight Loss HIV Wasting Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Signs and Symptoms, Digestive Signs and Symptoms Emaciation Body Weight Changes Metabolic Diseases Nutrition Disorders Megestrol Acetate Megestrol Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |